IKNA: ikenaoncology.com Company Value to Net Income

Ikena Oncology - graphic logo of issuer IKNA

Ikena Oncology, Inc. (IKNA) is developing innovative therapies for solid tumors, leveraging the secure scientific infrastructure of the US and the humanitarian status of medicine. The price history reflects a current P/E ratio of -2.20. However, the business faces intense pressure from global pharma behemoths that possess massive capital to promote alternative immunotherapeutic methods.

Price to Earnings Ratio: Ikena (IKNA) for 07/04/2022 - 08/09/2025

Comprehensive metric breakdowns and analytics for Ikena Oncology Inc. (IKNA)

- share price and expert price forecast:
- market capitalization information:
Summary company analysis:Ikena Oncology, Inc.
Flagship merchandise of Ikena Oncology

The P/E ratio reflects the market value of one dollar of net income, allowing for an assessment of the premium paid for an asset. This indicator measures the investment payback period assuming business income remains constant. However, the P/E ratio for Ikena Oncology, Inc. (IKNA) is often distorted due to negative earnings and R&D expenses. The high risk of clinical trial failure and liquidity shortages make the metric volatile. This signals the speculative nature of the capital valuation.

Analysis of competing companies

ONC: Company Value to Net Income|Price to Earnings Ratio HALO (Halozyme Inc.)|RVMD (RevMed) - Company Value to Net Income|P/E Multiple AAPG (ascentage.com)|CGON - Price to Earnings Ratio|URGN: Price to Earnings Ratio|BCAX - P/E Multiple|Personalis Corp (PSNL) - Price to Earnings Ratio|Erasca Corp - Company Value to Net Income|DCTH (Delcath Systems Inc) - P/E Multiple|Market Cap to Earnings Y-mAbs Therapeutics, Inc. YMAB|P/E Multiple AURA|Price to Earnings Ratio Candel Therapeutics, Inc. CADL|P/E Multiple ARAY (Accuray, Inc.)|SELLAS Life Sciences - Price to Earnings Ratio|ACTU: Price to Earnings Ratio|Citius Oncology, Inc. - Market Price to Net Income Ratio|HURA (TuHURA Biosciences) - Price to Earnings Ratio|TARA: Market Price to Net Income Ratio|Price to Earnings Ratio FATE|WHWK: Company Value to Net Income|Price to Earnings Ratio TCRX (TScan Therapeutics Inc)|Business Payback Period Champions Oncology Inc|P/E Multiple XBIT (XBiotech Inc.)|Company Value to Net Income CVM|OS Therapies Inc. - P/E Multiple|RADX - P/E Multiple|ARTV: P/E Multiple|ANL: Market Price to Net Income Ratio|Price to Earnings Ratio VERU|TPST: Company Value to Net Income|Price to Earnings Ratio xiliotx.com (XLO)|Renovaro - Price to Earnings Multiple|Price to Earnings Ratio Mural Oncology MURA|KAPA - Price to Earnings Ratio|OKUR - Price to Earnings Ratio|GDTC - P/E Multiple|Curis, Inc. (CRIS) - Price to Earnings Ratio|Price to Earnings Ratio Apollomics, Inc.|Price to Earnings Ratio THAR|Price to Earnings Multiple ADVB (Advanced Biomed)|Price to Earnings Ratio GNPX (Genprex, Inc)|CLDI: Market Cap to Net Income|Price to Earnings Ratio sunshinebiopharma.com SBFM|XBIO - Price to Earnings Ratio|SLRX: Price to Earnings Ratio|Purple Biotech - Market Price to Net Income Ratio|American Oncology Network (AONC) - Price to Earnings Ratio|Price to Earnings Multiple BGNE|Price to Earnings Ratio CKPT|Price to Earnings Ratio ELEV|P/E Multiple ICAD|Price to Earnings Ratio NTBL (Notable Labs, Ltd.)|P/E Multiple VIRX (viracta.com)|MOR - Price to Earnings Ratio|NAYA - Price to Earnings Ratio|Market Cap to Net Income AAPGV